Holen Sie sich die Stockscreener-App
5.85
4.65%
0.26
Handel nachbörslich:
5.84
-0.010
-0.17%
Schlusskurs vom Vortag:
$5.59
Offen:
$5.58
24-Stunden-Volumen:
111.56K
Relative Volume:
1.00
Marktkapitalisierung:
$175.08M
Einnahmen:
$31.37M
Nettoeinkommen (Verlust:
$-53.77M
KGV:
-4.0242
EPS:
-1.4537
Netto-Cashflow:
$-49.02M
1W Leistung:
+9.96%
1M Leistung:
-9.16%
6M Leistung:
+30.00%
1J Leistung:
-64.76%
1-Tages-Spanne:
$5.47
$6.21
1-Wochen-Bereich:
$4.425
$6.21
52-Wochen-Spanne:
$1.97
$20.48
Silence Therapeutics Plc Adr Stock (SLN) Company Profile
Firmenname
Silence Therapeutics Plc Adr
Sektor
Branche
Telefon
44-0-20-3457 6900
Adresse
72 HAMMERSMITH ROAD, LONDON
Vergleichen Sie SLN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLN
Silence Therapeutics Plc Adr
|
5.85 | 240.42M | 31.37M | -53.77M | -49.02M | -1.4537 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Silence Therapeutics Plc Adr Stock (SLN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Goldman | Sell |
| 2024-12-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
Silence Therapeutics Plc Adr Aktie (SLN) Neueste Nachrichten
William Blair Issues Pessimistic Forecast for SLN Earnings - Defense World
Silence Therapeutics earnings missed by $0.06, revenue fell short of estimates - Investing.com South Africa
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives $33.83 Average PT from Analysts - Defense World
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade - Yahoo.co
Stephens Inc. AR Invests $260,000 in Evergy Inc. (NASDAQ:EVRG) - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Price Up 20.7% – Still a Buy? - Defense World
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Beat the Market the Zacks Way: Credo, Palantir, Oracle in Focus - Yahoo Finance
Silence Therapeutics soars 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
H.C. Wainwright reiterates buy rating on Silence Therapeutics stock By Investing.com - Investing.com South Africa
Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet - MSN
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year By Investing.com - Investing.com India
Silence Therapeutics’s SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade - MSN
Silence Therapeutics stock hits 52-week low at $3.19 By Investing.com - Investing.com South Africa
Silence Therapeutics stock hits 52-week low at $3.19 - Investing.com
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know - MSN
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn - Investing.com
Silence Therapeutics stock hits 52-week low at $3.66 amid downturn By Investing.com - Investing.com South Africa
Taiwan Semiconductor Valuation: How Realistic Is the Price? - The Globe and Mail
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges - Investing.com
Silence Therapeutics stock hits 52-week low at $4.04 amid challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Silence Therapeutics sees stock rise post-earnings - Investing.com
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Goldman Sachs cuts Silence Therapeutics stock rating to Sell By Investing.com - Investing.com South Africa
Cloudflare Inc’s (NET) Stock: A 29.10% Simple Moving Average for the Past 20 Days - The News Heater
Silence Therapeutics's SWOT analysis: stock poised for growth amid challenges - Investing.com
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels - Yahoo Finance
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.28% - Investing.com
Zerlasiran shows promise in phase 2 study for cardiovascular risk - Investing.com India
Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Silence Therapeutics to Join Guggenheim Biotech Conference By Investing.com - Investing.com India
Here's Why Momentum in Silence Therapeutics PLC Sponsored ADR (SLN) Should Keep going - Nasdaq
symbol__ Stock Quote Price and Forecast - CNN
BioCryst (BCRX) Surges 9.9%: Is This an Indication of Further Gains? - Nasdaq
Claire Keast-Butler - Cooley
Our approach to nucleotide-based therapeutics - AstraZeneca
5 Stocks to Buy as the Drug Industry Bets Big on Innovation - Nasdaq
Silence Therapeutics PLC Sponsored ADR (SLN) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
SLN News Today | Why did Silence Therapeutics stock drop today? - MarketBeat
Silence Therapeutics (SLN) Stock Price, News & Analysis - MarketBeat
Silence Therapeutics (SLN) - Zacks Investment Research
Finanzdaten der Silence Therapeutics Plc Adr-Aktie (SLN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):